-
Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically
Time of Update: 2021-01-19
in clinical stage, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection. 's single anti-HLX55 has also been approved
-
Song Ruixuan, Executive Chairman of the Chinese Pharmaceutical Promotion Association, met with counsellors from the Dutch Embassy in Beijing
Time of Update: 2021-01-18
to the two sides continuing to deepen cooperation and jointly promote the exchange and development of the pharmaceutical industry between China and the Netherlands. Said that the current world political and economic situation is facing great changes
-
Shaanxi Governor Zhao Yide met with representatives of Qin Shang, chairman of Ted Pharmaceuticals, Zheng Xiangling
Time of Update: 2021-01-11
a critical period of high-quality development, I hope you will seize the opportunity to increase investment in Shaanxi, to help the hometown to achieve better and faster development. we will continue to optimize the business environment
-
Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically
Time of Update: 2021-01-09
, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection. 's single anti-HLX55 has also been approved for clinical
-
Song Ruixuan, Executive Chairman of the China Drug Promotion Association, met with Peng Lixuan, Counselor of the Singapore 鈱 Embassy
Time of Update: 2021-01-03
On the afternoon of December 21, 2020, Song Ruixuan, Executive Chairman of the China Pharmaceutical Innovation Promotion Association (the "China Pharmaceutical Promotion Association"), met with Mr. Peng , Counselor of the Singapore Embassy in China
-
Johnson and Johnson EGFR/c-Met dual resistance to market application with Phase I data
Time of Update: 2021-01-03
fda has not yet approved targeted therapies specifically for patients with EGFR exon 20 insertion mutation NSCLC, amivantamab is the first drug to be marketed to regulators for treatment of such patients.
-
EGFR-MET dual-specific antibodies! Johnson and Johnson amivantamab apply for listing: Treatment of EGFR exon 20 insertion mutation lung cancer (NSCLC)!
Time of Update: 2020-12-20
for amivantamab treatment during the BLA review. amivantamab is an all-human EGFR-interstital dermistic transformation factor (MET) dual-specific antibody in study with immune cell-oriented activity, targeting tumors carrying activated and drug
-
Four requirements need to be met before the construction of epoxy sand floor paint
Time of Update: 2020-12-19
3, if it is the old floor refurbishment, the construction personnel need to use cleaning tools will be the original ground loose layer, cement stains, lime film and other foreign objects.
-
What will be met after the floor of the underground garage has been laid?
Time of Update: 2020-11-27
to use. So what aspects of quality should be up to standard after the underground garage floor is laid? to meet the standards after laying the floor of the underground garage? 1. Curing quality to meet the standards specializing
-
NEJM: Targeting the MET path path, long-lasting remission in patients with specific advanced non-small cell lung cancer
Time of Update: 2020-11-16
a total of 152 patients diagnosed with the MET exon 14 jump mutation received tepotinib treatment, of which 99 patients received follow-up for at least 9 months.
-
The third generation of NMN Serai Fu NADH came out of the sky, thousands of miles of horse finally met Bole!
Time of Update: 2020-11-04
of NADH science to delay aging hard strength NADH is indeed low-key for nearly a hundred years, both in terms of efficacy and scientific research, are stronger than the "longevity drug" NMN, but because NMN has Some business tycoons endorsement, soon
-
The combination therapy of Johnson and Johnson EGFR-MET and third generation EGFR-TKI was approved in 4 clinical trials in China
Time of Update: 2020-11-03
billion in 2018. Photo Source: CDE Screenshot Amivantamab (code: JNJ-6372) is a dual-specific antibody that targets EGFR and MET, which not only blocks ligand binding to EGFR and MET, promotes the degradation of the subject, but also triggers
-
Alice Pharma introduced two MET inhibitors to focus on the development of lung cancer combination therapy.
Time of Update: 2020-10-12
OMO-1 is an oral highly selective small molecule MET kinase inhibitor that has been shown to be effective in a series of preclinical cancer models.
-
Johnson and Johnson EGFR-MET dual resistance and third-generation EGFR-TKI combination therapy were approved for 4 clinical trials in China.
Time of Update: 2020-10-04
amivantamab injection/lazertinib tablet combination drug for the treatment of NSCLC patients with EGFR 19 exon loss or L858R activation mutations, treated with oghitinib or other approved third-generation EGFR TKI, and progression of the disease after platinum-containing dual-drug chemotherapy.
-
The Johnson and Johnson EGFR-MET combination therapy was approved for a clinical trial of oxytinib-resistant NSCLC.
Time of Update: 2020-09-30
-20). results reported at the ESMO conference showed that the amivantamab-Lazertinib drug was 100% ORR for 20 EGFR primary patients, including 20 PR patients. follow-up time and the medium treatment time of 7 months, mDOR has not yet
-
Treatment of specific non-small cell lung cancer patients Merck MET inhibitors in Germany was reviewed by the FDA as a priority.
Time of Update: 2020-09-28
1.9 million lung cancer deaths worldwide each year.
-
NEJM:Tepotinib treated met exon 14 jump mutation non-small cell lung cancer phase II clinical effect was significant.
Time of Update: 2020-09-23
study, tepotinib treatment response rate was about 50% for patients with advanced non-small cell lung cancer with met exon 14 jump mutation, and the most common adverse events above level 3 were exostular edema.
-
Why is the exterior wall painted white when water is met? The reason is here, please collect!
Time of Update: 2020-08-22
The water resistance of the real stone paint is reduced, and it is easy to whiten after the rain washes away.
-
A 60-year-old Uighur woman suffered a heart attack on the plane, but luckily she met seven doctors who helped her!
Time of Update: 2020-08-19
Beijing Zhongguancun Hospital aid and Tian medical team of 7 people happened to take this flight, expert group member, vice president Pan Mingkang immediately got up to find the crew, "We are doctors, where are the patients ?" That's great!
-
c-Met inhibitors enter harvest period: 2 milestone drugs approved dozens of domestic drugs clinical.
Time of Update: 2020-08-02
) is a highly binding receptor tyrosine kinase, belonging to the RON subnational, is the only known receptor of hepatocellular growth factor (HGF). in NSCLC, which accounts for 80%-85% of lung cancer, 3%-5% of patients develop met gene
